Value of 18F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: Systematic review and meta-analysis

American Journal of Roentgenology

Volumn 204, Issue 6, 2015, Pages 1261-1268

  Maffione, Anna Margherita ^a   Marzola, Maria Cristina ^a   Capirci, Carlo ^a   Colletti, Patrick M ^b   Rubello, Domenico ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

FDG PET CT; Locally advanced rectal cancer; Meta analysis; Predictive value; Preoperative chemoradiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; CANCER ADJUVANT THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; RECTUM CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR VOLUME; CHEMORADIOTHERAPY; DIAGNOSTIC USE; FEMALE; MALE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROCEDURES; PROGNOSIS; RECTAL NEOPLASMS; REPRODUCIBILITY; RISK ASSESSMENT; SCINTISCANNING; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CHEMORADIOTHERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; RECTAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84937683398     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.14.13210     Document Type: Article

References (63)

1. Delbeke D, Walker R. Colorectal cancer. In Delbeke D, Israel O, eds. Hybrid PET/CT and SPECT/CT imaging. New York, NY: Springer, 2010:261-292
2. Lynch TB. Colorectal cancer. In Lynch TB. PET/CT in clinical practice. New York, NY: Springer, 2007:93-115
3. Gil-delgado MA, Khayat D. Cancro del colon e del retto. In Pollock RE, Doroshok JH, Khayat D, Nakao A, O'Sullivah B, eds. UICC manuale di oncologia clinica. Torino, Italy: Minerva Medica, 2008:511-529
4. Murcia Duréndez MJ, Frutos Esteban L, Luján J, et al. The value of 18F-FDG PET/CT for assessing the response to neoadjuvant therapy in locally advanced rectal cancer. Eur J Nucl Med Mol Imaging 2013; 40:91-97
5. Bosset JF, Collette L, Calais G, et al. EORTC Radiotherapy Group Trial 22921: chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114-1123
6. De Paoli A, Chiara S, Luppi G, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006; 17:246-251
7. Graf W, Dahlberg M, Osman MM, Holmberg L, Pählman L, Glimelius B. Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol 1997; 43:133-137
8. Janjan NA, Khoo VS, Rich TA, et al. Locally advanced rectal cancer: surgical complications after infusional chemotherapy and radiation therapy. Radiology 1998; 206:131-136
9. Goldberg N, Kundel Y, Purim O, et al. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18F-FDG PET-CT imaging: a prospective clinical study. Radiat Oncol 2012; 7:124
10. García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003; 46:298-304
11. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23:8688-8696
12. Rosenberg R, Nekarda H, Zimmermann F, et al. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. J Surg Oncol 2008; 97:8-13
13. Leibold T, Akhurst TJ, Chessin DB, et al. Evaluation of 18F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. Ann Surg Oncol 2011; 18:2783-2789
14. Sauer R, Becker H, Hohenberger W, et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731-1740
15. Medich D, McGinty J, Parda D, et al. Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum 2001; 44:1123-1128
16. Onaitis MW, Noone RB, Fields R, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 2001; 8:801-806
17. Habr-Gama A, Perez RO, Nadalin W, et al. Longterm results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005; 9:90-99
18. Pucciarelli S, Toppan P, Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 2004; 47:1798-1807
19. Valentini V, Coco C, Cellini N, et al. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys 2001; 51:371-383
20. Capirci C, Rubello D, Chierichetti F, et al. Longterm prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR 2006; 187:[web]W202-W208
21. Huh JW, Min JJ, Lee JH, Kim HR, Kim YJ. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation. Am J Clin Oncol 2012; 35:340-344
22. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240:711-717
23. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50(suppl 1):122S-150S
24. Janssen MH, Öllers MC, van Stiphout RG, et al. PET-based treatment response evaluation in rectal cancer: prediction and validation. Int J Radiat Oncol Biol Phys 2012; 82:871-876
25. Avallone A, Aloj L, Caracò C, et al. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging 2012; 39:1848-1857
26. Herrmann K, Bundschuh RA, Rosenberg R, et al. Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI. Mol Imaging Biol 2011; 13:1011-1019
27. Capirci C, Rubello D, Pasini F, et al. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiat Oncol Biol Phys 2009; 74:1461-1469
28. Melton GB, Lavely WC, Jacene HA, et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 2007; 11:961-969
29. Guillem JG, Puig-La Calle J Jr, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000; 43:18-24
30. National Comprehensive Cancer Network website. NCCN clinical practice guidelines in oncology. rectal cancer. version 2.2014. www.nccn.org/professionals/physician-gls/f-guidelines. asp#site. Accessed February 26, 2015
31. Bockisch A. Freudenberg LS, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med 2009; 39:276-289
32. Song I, Kim SH, Lee SJ, Choi JY, Kim MJ, Rhim H. Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging. Br J Radiol 2012; 85:577-586
33. Martoni AA, Di Fabio F, Pinto C, et al. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol 2011; 22:650-656
34. Lambrecht M, Deroose C, Roels S, et al. The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol 2010; 49:956-963
35. Cho YB, Chun HK, Kim MJ, et al. Accuracy of MRI and 18F-FDG PET/CT for restaging after preoperative concurrent chemoradiotherapy for rectal cancer. World J Surg 2009; 33:2688-2694
36. Kristiansen C, Loft A, Berthelsen AK, et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum 2008; 51:21-25
37. Bampo C, Alessi A, Fantini S, et al. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabinebased neoadjuvant chemoradiation? Oncology 2013; 84:191-199
38. Sun W, Xu J, Hu W, Zhang Z, Shen W. The role of sequential 18(F)-FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer. Colorectal Dis 2013; 15:e231-e238
39. Shanmugan S, Arrangoiz R, Nitzkorski JR, et al. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT. Ann Surg Oncol 2012; 19:2178-2185
40. Kalff V, Ware R, Heriot A, Chao M, Drummond E, Hicks RJ. Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. Int J Radiat Oncol Biol Phys 2009; 74:60-66
41. Hur H, Kim NK, Yun M, et al. 18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer. 2011; 103:17-24
42. Capirci C, Rampin L, Erba PA, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging 2007; 34:1583-1593
43. Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging 2013; 40:853-864
44. Ippolito D, Monguzzi L, Guerra L, et al. Response to neoadjuvant therapy in locally advanced rectal cancer: assessment with diffusion-weighted MR imaging and 18FDG PET/CT. Abdom Imaging 2012; 37:1032-1040
45. Yoon HJ, Kim SK, Kim TS, et al. New application of dual point 18F-FDG PET/CT in the evaluation of neoadjuvant chemoradiation response of locally advanced rectal cancer. Clin Nucl Med 2013; 38:7-12
46. Yoon MS, Ahn SJ, Nah BS, et al. The metabolic response using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography and the change in the carcinoembryonic antigen level for predicting response to pre-operative chemoradiotherapy in patients with rectal cancer. Radiother Oncol 2011; 98:134-138
47. Guerra L, Niespolo R, Di Pisa G, et al. Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. Abdom Imaging 2011; 36:38-45
48. Hatt M, van Stiphout R, le Pogam A, Lammering G, Visvikis D, Lambin P. Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET. Acta Oncol 2013; 52:619-626
49. Choi H, Yoon HJ, Kim TS, Oh JH, Kim DY, Kim SK. Voxel-based dual-time 18F-FDG parametric imaging for rectal cancer: differentiation of residual tumor from postchemoradiotherapy changes. Nucl Med Commun 2013; 34:1166-1173
50. Maffione AM, Ferretti A, Chondrogiannis S, et al. Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria. Clin Nucl Med 2013; 38:795-797
51. Calvo FA, Sole CV, de la Mata D, et al. 18F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes. Eur J Nucl Med Mol Imaging 2013; 40:657-667
52. Rosenberg R, Herrmann K, Gertler R, et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis 2009; 24:191-200
53. Everaert H, Hoorens A, Vanhove C, et al. Prediction of response to neoadjuvant radiotherapy in patients with locally advanced rectal cancer by means of sequential 18FDG-PET. Int J Radiat Oncol Biol Phys 2011; 80:91-96
54. Palma P, Conde-Muíño R, Rodríguez-Fernández A, et al. The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer. Radiat Oncol 2010; 5:119
55. Vliegen RF, Beets-Tan RG, Vanhauten B, et al. Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer? Strahlenther Onkol 2008; 184:457-464
56. Chennupati SK, Quon A, Kamaya A, et al. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Am J Clin Oncol 2012; 35:334-339
57. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative CRT of esophageal carcinoma: clinicopathologic correlations. Cancer 1994; 73:2680-2686
58. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12:19-23
59. Guillem JG, Ruby JA, Leibold T, et al. Neither FDG-PET nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg 2013; 258:289-295
60. Kaira K, Endo M, Asakura K, et al. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer. Ann Nucl Med 2010; 24:697-705
61. Cazaentre T, Morschhauser F, Vermandel M, et al. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010; 37:494-504
62. Li C, Lan X, Yuan H, Feng H, Xia X, Zhang Y. 18F-FDG PET predicts pathological response to preoperative chemoradiotherapy in patients with primary rectal cancer: a meta-analysis. Ann Nucl Med 2014; 28:436-446
63. Zhang C, Tong J, Sun X, Liu J, Wang Y, Huang G. 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis. Int J Cancer 2012; 131:2604-2611